PharmaShots Weekly Snapshots (June 14 – 18, 2021)

 PharmaShots Weekly Snapshots (June 14 – 18, 2021)

Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem

Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Published: June 18, 2021 | Tags: BioNTech, P-II, Clinical Trial, BNT111, Advanced Melanoma

CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma

Published: June 18, 2021 | Tags: CytoReason, Project, Utilizing, Sanofi, AI Technology, Asthma

BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

Published: June 18, 2021 | Tags: BeiGene, P-III, AdvanTIG-302 Trial, Ociperlimab, BGB-A1217, Tislelizumab, BGB-A317 Non-Small Cell Lung Cancer

Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies

Published: June 18, 2021 | Tags: Kite, Shoreline Biosciences, Develop, Novel Allogeneic Cell Therapies

Biogen Reports First Patient Dosing in P-III TOPAZ-1 Study of BIIB059 to Treat Systemic Lupus Erythematosus

Published: June 18, 2021 | Tags: Biogen, P-III, TOPAZ-1 Study, BIIB059, Systemic Lupus Erythematosus

Biogen’s Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Published: June 17, 2021 | Tags: Biogen, Gosuranemab, BIIB092, Primary Endpoint, P-II, TANGO Study Alzheimer Disease

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Published: June 17, 2021 | Tags: Atea Pharma, Milestone Payment, License Agreement, Roche, AT-527

Blueprint Medicines’ Ayvakit (avapritinib) Receives FDA’s Approval to Treat Patients with Advanced Systemic Mastocytosis

Published: June 17, 2021 | Tags: Blueprint Medicines, Ayvakit, avapritinib, FDA, Approval, Advanced Systemic Mastocytosis

CureVac Report Results of CVnCoV in Second Interim Analysis of P-llb/lll HERALD Trial to Treat COVID-19

Published: June 17, 2021 | Tags: CureVac, Second Interim Analysis, P-llb/lll HERALD Trial, CVnCoV, COVID-19

MannKind and United Therapeutics Reports the US FDA’s Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD

Published: June 17, 2021 | Tags: MannKind, United Therapeutics, US, FDA, Acceptance, NDA, Priority Review, Tyvaso DPI, PAH, PH-ILD

Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM

Published: June 17, 2021 | Tags: Pfizer, Tofacitinib, STOP-COVID Study, COVID-19 Pneumonia, NEJM

Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA

Published: June 16, 2021 | Tags: Lundbeck, Vyepti, eptinezumab-jjmr, RELIEF Study, Migraine, JAMA

Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19

Published: June 16, 2021 | Tags: Organicell, Expanded Access Trial, Zofin, COVID-19

Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III RECOVERY Trial for COVID-19 Patients

Published: June 16, 2021 | Tags: Regeneron, REGEN-COV, Casirivimab, Imdevimab, P-III, RECOVERY Trial, COVID-19

Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies

Published: June 16, 2021 | Tags: Gilead, Jounce, JTX-1811, US, FDA, IND, Clearance, Cancer Immunotherapies

Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer

Published: June 16, 2021 | Tags: Linnaeus Therapeutics, Clinical Collaboration, Merck, LNS8801, Keytruda, Advanced Cancer

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Published: June 16, 2021 | Tags: Innovent, P-II, Clinical Trial, Obesity, China

Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder

Published: June 15, 2021 | Tags: Sage, Biogen, Zuranolone, P-III, WATERFALL Study, Depressive Disorder

AstraZeneca’s AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19

BeiGene’s Tislelizumab in Combination with Asieris’ APL-1202 Receive the US FDA’s IND Approval for MIBC

Published: June 15, 2021 | Tags: BeiGene, Tislelizumab, Asieris, APL-1202, US, FDA, IND, Approval,  MIBC

AstraZeneca’s AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19

Novavax’s COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study

Published: June 15, 2021 | Tags: Novavax, COVID-19 Vaccine, 90.4% Efficacy, P-III, PREVENT-19 Study

Biogen’s BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia

Published: June 15, 2021 | Tags: Biogen, BIIB111, Primary Endpoint, P-III, STAR Study,  Choroideremia

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer

Published: June 14, 2021 | Tags: GSK, iTeos Therapeutics, Co-Develop, Commercialize, EOS-448, Cancer

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Published: June 14, 2021 | Tags: Kite, Yescarta, axicabtagene ciloleucel, P-II, ZUMA-5 Trial, R/R Follicular Lymphoma, EHA 2021

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021

Published: June 14, 2021 | Tags: AbbVie, Imbruvica, ibrutinib, Venclexta, Venclyxto, venetoclax, P-III, GLOW Study, CLL, SLL, EHA 2021

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Published: June 14, 2021 | Tags: Janssen, Darzalex, daratumumab, P-III, MAIA Study, Multiple Myeloma, EHA 2021

Celltrion Presents Real-World Data of Truxima (biosimilar, rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021

Published: June 14, 2021 | Tags: Celltrion Healthcare, Truxima, biosimilar, rituximab, Diffuse Large B-Cell Lymphoma, EHA 2021

Sanofi Presents Results of Sutimlimab in P-III CADENZA Trial to Treat Hemolysis Patients with Cold Agglutinin Disease at EHA 2021

Published: June 14, 2021 | Tags: Sanofi, Sutimlimab, Part A, P-III, CADENZA Trial, Hemolysis, Cold Agglutinin Disease, EHA 2021

Related Post: PharmaShots Weekly Snapshots (June 07 – 11, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post